Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:22 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:22 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
Zacks News
The Zacks Analyst Blog Highlights: Merck, PayPal, Royal Dutch Shell, BlackRock and General Electric
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, PayPal, Royal Dutch Shell, BlackRock and General Electric
Exelixis (EXEL) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exelixis (EXEL) beats on earnings and sales in the first quarter and maintains annual outlook amid coronavirus.
Top Research Reports for Merck, PayPal & Royal Dutch Shell
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), PayPal (PYPL) and Royal Dutch Shell (RDS.A).
Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.
Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More
by Kinjel Shah
Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.
5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Epizyme (EPZM) reports a narrower-than-expected Q1 loss but misses on revenues.
Seattle Genetics (SGEN) Q1 Earnings Beat, Adcetris Aids Sales
by Zacks Equity Research
Seattle Genetics (SGEN) reports narrower-than-expected loss in Q1 while its revenues too beat estimates.
Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Progress of its pipeline candidates, especially coronavirus vaccine, is likely to have increased Moderna's (MRNA) operating expenses in the first quarter.
Factors Setting the Tone for Bristol-Myers (BMY) Q1 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports first-quarter 2020 results.
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
AstraZeneca (AZN) Q1 Earnings & Sales Beat, Increase Y/Y
by Zacks Equity Research
AstraZeneca (AZN) beats estimates for both earnings and sales. It maintains its financial outlook for the year.
Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More
by Zacks Equity Research
Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) Q1 top line is likely to have been impacted by biosimilar competition for Humira in international markets. However, oncology drugs may have demonstrated strong growth.
Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) beats estimates for earnings as well as for sales in first-quarter 2019. The company lowers its sales and earnings guidance to include impact of COVID-19. Shares down.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
A Plethora of Q1 Earnings Results: MMM, CAT, PEP & More
by Mark Vickery
A big morning for Q1 earnings reports joins a new Advance Trade in Goods report out this morning. Pre-market indexes are way in the green at this hour.
Merck (MRK) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 7.91% and 2.09%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Big Drug Stock Q1 Earnings Due on Apr 28: MRK, PFE and NVS
by Kinjel Shah
Let us take a look at three big drug companies due to release their first-quarter financial results on Apr 28.
3 Top Dividend Stocks to Maximize Your Retirement Income - April 27, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Will Pfizer's (PFE) BioPharma Unit Q1 Earnings Increase?
by Zacks Equity Research
In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the first quarter, while in non-oncology, Xeljanz and Eliquis alliance revenues are likely to have supported the top line.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $80.88, moving +1.13% from the previous trading session.
Merck (MRK) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's (MRK) performance when it reports first-quarter results.
Immunomedics Wins Fast FDA Approval for Breast Cancer Drug
by Zacks Equity Research
The FDA nods to Immunomedics' (IMMU) Trodelvy for treating patients with metastatic triple-negative breast cancer, having previously received minimum two therapies. Stock rallies in pre-market trading.
Healthcare ETFs Looks Strong Ahead of Q1 Earnings
by Sweta Killa
The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.